P
ProQR Therapeutics N.V. (PRQR)
1.37
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
1.37
0.00 (0.00%)
ProQR Therapeutics N.V., klinik bosqichdagi biotexnologiya kompaniyasi, yangi terapevtik dorilarni kashf qilish va rivojlantirishga qaratilgan. Kompaniya Axiomer RNKni tahrirlash texnologiyasi orqali RNKni tahrirlash platformasini ishlab chiqmoqda, bu esa o'ziga xos ehtiyojlari bo'lgan genetik kasalliklar uchun mo'ljallangan. Uning asosiy mahsulot nomzodi, AX-0810, xolestatik kasalliklarni davolash uchun na-tauroxolat kotransport qiluvchi polipeptid (NTCP) ga qaratilgan. Kompaniya shuningdek, Rett sindromi uchun metil CpG bog'lovchi oqsil 2 mutatsiyalariga qaratilgan AX-2402; metabolik disfunksiya bilan bog'liq steatohepatit uchun PNPLA3 ga qaratilgan AX-2911; va yurak-qon tomir kasalliklari uchun B4GALT1 geniga qaratilgan AX-1412 ni ishlab chiqmoqda. Kompaniya Eli Lilly and Company bilan jigar va nerv sistemasidagi genetik kasalliklar uchun potentsial yangi dorilarni kashf qilish, ishlab chiqish va tijoratlashtirish bo'yicha tadqiqot va hamkorlik shartnomasiga ega. Kompaniya 2012 yilda ro'yxatdan o'tgan va Niderlandiyaning Leyden shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Cristina Lopez Lopez M.D., Ph.D. | Chief Medical Officer |
| Dr. Gerard Platenburg Ph.D. | Co-Founder, Chief Scientific Officer & Executive Director |
| Mr. Daniel Anton de Boer | Founder, CEO & Executive Director |
| Mr. Dennis Hom | Chief Financial Officer |
| Ms. Sandra van der Kolk | Junior Financial Controller |
| Ms. Sarah Cue Kiely | Vice President of Investor Relations & Corporate Communications |
| Ms. Sheila Sponselee | Chief People & Operations Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-12 | 20-F | prqr-20251231x20f.htm |
| 2026-01-08 | 6-K | tm262448d1_6k.htm |
| 2025-11-06 | 6-K | prqr-20250930x6k.htm |
| 2025-11-03 | 6-K | tm2529990d1_6k.htm |
| 2025-10-20 | 6-K | tm2529012d1_6k.htm |
| 2025-08-07 | 6-K | tmb-20250630x6k.htm |
| 2025-06-26 | 6-K | tm2519211d1_6k.htm |
| 2025-06-03 | 6-K | tm2516972d1_6k.htm |
| 2025-05-08 | 6-K | tmb-20250331x6k.htm |
| 2025-05-01 | 6-K | tm2513537d1_6k.htm |